2023 Journal Article COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasisHancock, Janelle L., Kalimutho, Murugan, Straube, Jasmin, Lim, Malcolm, Gresshoff, Irma, Saunus, Jodi M., Lee, Jason S., Lakhani, Sunil R., Simpson, Kaylene J., Bush, Ashley I., Anderson, Robin L. and Khanna, Kum Kum (2023). COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. Journal of Experimental and Clinical Cancer Research, 42 (1) 90, 1-16. doi: 10.1186/s13046-023-02663-8 |
2023 Journal Article Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinomaRaninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011 |
2022 Journal Article CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitorsLu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V. and Khanna, Kum Kum (2022). CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Journal of Experimental and Clinical Cancer Research, 41 (1) 355, 1-17. doi: 10.1186/s13046-022-02570-4 |
2021 Journal Article Increased susceptibility of cystic fibrosis airway epithelial cells to ferroptosisManiam, Pramila, Essilfie, Ama-Tawiah, Kalimutho, Murugan, Ling, Dora, Frazer, David M., Phipps, Simon, Anderson, Gregory J. and Reid, David W. (2021). Increased susceptibility of cystic fibrosis airway epithelial cells to ferroptosis. Biological Research, 54 (1) 38. doi: 10.1186/s40659-021-00361-3 |
2021 Journal Article Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesisRashidieh, Behnam, Shohayeb, Belal, Bain, Amanda Louise, Fortuna, Patrick R. J., Sinha, Debottam, Burgess, Andrew, Mills, Richard, Adams, Rachael C., Lopez, J. Alejandro, Blumbergs, Peter, Finnie, John, Kalimutho, Murugan, Piper, Michael, Hudson, James Edward, Ng, Dominic C. H. and Khanna, Kum Kum (2021). Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesis. PLoS Genetics, 17 (10) e1009334, 1-31. doi: 10.1371/journal.pgen.1009334 |
2021 Journal Article Targeting BRF2 in cancer using repurposed drugsRashidieh, Behnam, Molakarimi, Maryam, Mohseni, Ammar, Tria, Simon Manuel, Truong, Hein, Srihari, Sriganesh, Adams, Rachael C., Jones, Mathew, Duijf, Pascal H. G., Kalimutho, Murugan and Khanna, Kum Kum (2021). Targeting BRF2 in cancer using repurposed drugs. Cancers, 13 (15) 3778, 1-28. doi: 10.3390/cancers13153778 |
2021 Journal Article CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancerMakhale, Ashwini, Nanayakkara, Devathri, Raninga, Prahlad, Khanna, Kum Kum and Kalimutho, Murugan (2021). CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. International Journal of Molecular Sciences, 22 (11) 5782, 5782. doi: 10.3390/ijms22115782 |
2020 Journal Article Cep55 overexpression promotes genomic instability and tumorigenesis in miceSinha, Debottam, Nag, Purba, Nanayakkara, Devathri, Duijf, Pascal H. G., Burgess, Andrew, Raninga, Prahlad, Smits, Veronique A. J., Bain, Amanda L., Subramanian, Goutham, Wall, Meaghan, Finnie, John. W., Kalimutho, Murugan and Khanna, Kum Kum (2020). Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Communications Biology, 3 (1) 593, 1-16. doi: 10.1038/s42003-020-01304-6 |
2020 Journal Article Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancerRaninga, Prahlad V., Lee, Andy C., Sinha, Debottam, Shih, Yu-Yin, Mittal, Deepak, Makhale, Ashwini, Bain, Amanda L., Nanayakarra, Devathri, Tonissen, Kathryn F., Kalimutho, Murugan and Khanna, Kum Kum (2020). Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. International Journal of Cancer, 146 (1), 123-136. doi: 10.1002/ijc.32410 |
2020 Journal Article Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionRaninga, Prahlad, Lee, Andy, Sinha, Debottam, Dong, Lan-feng, Datta, Keshava, Lu, Xue, Kalita-de Croft, Priyakshi, Dutt, Mriga, Hill, Michelle M., Pouliot, Normand M., Gowda, Harsha, Kalimutho, Murugan, Neuzil, Jiri and Khanna, Kum Kum (2020). Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics, 10 (12), 5259-5275. doi: 10.7150/thno.42705 |
2019 Journal Article LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018)Boulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K. and Rao, S. (2019). LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018). Scientific Reports, 9 18771. doi: 10.1038/s41598-019-55020-1 |
2019 Journal Article Mechanisms of genomic instability in breast cancerDuijf, Pascal H.G., Nanayakkara, Devathri, Nones, K., Srihari, Sriganesh, Kalimutho, Murugan and Khanna, Kum Kum (2019). Mechanisms of genomic instability in breast cancer. Trends in Molecular Medicine, 25 (7), 595-611. doi: 10.1016/j.molmed.2019.04.004 |
2019 Journal Article MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cellsYang, Ren-Ming, Nanayakkara, Devathri, Kalimutho, Murugan, Mitra, Partha, Khanna, Kum Kum, Dray, Eloise and Gonda, Thomas J. (2019). MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells. Oncogene, 38 (26), 5239-5249. doi: 10.1038/s41388-019-0789-3 |
2019 Journal Article Patterns of genomic instability in breast cancerKalimutho, Murugan, Nones, Katia, Srihari, Sriganesh, Duijf, Pascal H.G., Waddell, Nicola and Khanna, Kum Kum (2019). Patterns of genomic instability in breast cancer. Trends in Pharmacological Sciences, 40 (3), 198-211. doi: 10.1016/j.tips.2019.01.005 |
2019 Journal Article Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancerKalimutho, Murugan, Sinha, Debottam, Mittal, Deepak, Srihari, Sriganesh, Nanayakkara, Devathri, Shafique, Shagufta, Raninga, Prahlad, Nag, Purba, Parsons, Kate and Khanna, Kum Kum (2019). Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 38 (1) 85, 1-18. doi: 10.1186/s13046-019-1075-5 |
2018 Journal Article CEP55 is a determinant of cell fate during perturbed mitosis in breast cancerKalimutho, Murugan, Sinha, Debottam, Jeffery, Jessie, Nones, Katia, Srihari, Sriganesh, Fernando, Winnie C., Duijf, Pascal H. G., Vennin, Claire, Raninga, Prahlad, Nanayakkara, Devathri, Mittal, Deepak, Saunus, Jodi M., Lakhani, Sunil R., López, J Alejandro, Spring, Kevin J., Timpson, Paul, Gabrielli, Brian, Waddell, Nicola and Khanna, Kum Kum (2018). CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 10 (9) e8566. doi: 10.15252/emmm.201708566 |
2018 Journal Article Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signalingSinha, Debottam, Kalimutho, Murugan, Bowles, Josephine, Chan, Ai-Leen, Merriner, D. Jo, Bain, Amanda L., Simmons, Jacinta L., Freire, Raimundo, Lopez, J Alejandro, Hobbs, Robin M., O'Bryan, Moira K. and Khanna, Kum Kum (2018). Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling. The FASEB Journal, 32 (9), 4984-4999. doi: 10.1096/fj.201701096RR |
2018 Journal Article GSK3β inhibition confers survival advantage in Burkholderia pseudomallei-infected hyperglycaemic mice by regulating inflammatory responseManiam, P., Kalimutho, M., Embi, N. and Sidek, H. M. (2018). GSK3β inhibition confers survival advantage in Burkholderia pseudomallei-infected hyperglycaemic mice by regulating inflammatory response. Tropical Biomedicine, 35 (1), 228-238. |
2018 Journal Article LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancerBoulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K. and Rao, S. (2018). LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Scientific Reports, 8 (1) 73. doi: 10.1038/s41598-017-17913-x |
2017 Journal Article Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiaeKalimutho, Murugan, Bain, Amanda L., Mukherjee, Bipasha, Nag, Purba, Nanayakkara, Devathri M., Harten, Sarah K., Harris, Janelle L., Subramanian, Goutham N., Sinha, Debottam, Shirasawa, Senji, Srihari, Sriganesh, Burma, Sandeep and Khanna, Kum Kum (2017). Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Molecular Oncology, 11 (5), 470-490. doi: 10.1002/1878-0261.12040 |